US Tissue Diagnostics Market Size, Trends and Insights By Technology (In Situ Hybridization, Immunohistochemistry, Digital Pathology and workflow, Primary and Special Staining, Anatomic Pathology), By Application (Prostate Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Other Cancer), By End Users (Research Laborat…
The US tissue diagnostics market was valued at USD 2.02 Bn in 2023 and is projected to reach USD 3.66 Bn by 2032, growing at a CAGR of 6.8%. USA is both the largest and the fastest-growing regional market.
Reports Description
As per the current market research conducted by CMI Team, the US Tissue Diagnostics Market is expected to record a CAGR of 6.8% from 2023 to 2032. In 2023, the market size is projected to reach a valuation of USD 2,017.2 Million. By 2032, the valuation is anticipated to reach USD 3,655.5 Million.
The US Tissue Diagnostics Market encompasses the industry involved in the precise examination and analysis of tissue samples for accurate disease detection and diagnosis. Key players, including Roche Diagnostics and Thermo Fisher Scientific, contribute to advancements through technologies like digital pathology and molecular diagnostics.
Trends driving the market include a focus on personalized medicine, integration of artificial intelligence, and an increasing emphasis on early disease detection. With a growing aging population and continuous research investments, the market plays a pivotal role in enhancing healthcare outcomes by offering sophisticated diagnostic solutions tailored to individual patient needs.
US Tissue Diagnostics Market - Significant Growth Factors
Technological Advancements: Continuous innovations, such as digital pathology and molecular diagnostics, drive the US Tissue Diagnostics Market. These advancements enhance diagnostic precision, improve workflow efficiency, and contribute to the overall growth of the market.
Rising Incidence of Chronic Diseases: The increasing prevalence of chronic diseases, particularly cancer, is a major driver. Tissue diagnostics play a crucial role in early detection, precise diagnosis, and personalized treatment planning.
Aging Population: The demographic shift towards an aging population in the US increases the incidence of age-related diseases, fostering the demand for tissue diagnostics and supporting market growth.
Government Initiatives and Healthcare Investments: Supportive government initiatives, increased investments in healthcare infrastructure, and research funding create a favorable environment for market growth, facilitating advancements in tissue diagnostics technologies and services.
Integration of Artificial Intelligence (AI): The incorporation of AI presents a significant opportunity. AI applications in tissue diagnostics can enhance data analysis, improve diagnostic accuracy, and streamline pathology workflows, fostering innovation and growth.
Collaborations and Research Partnerships: Opportunities lie in collaborations between industry players, research institutions, and healthcare providers. Strategic partnerships can lead to the development of novel diagnostic solutions, addressing unmet needs and expanding the market's capabilities.
US Tissue Diagnostics Market - Mergers and Acquisitions
The US Tissue Diagnostics Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the US Tissue Diagnostics Market include:
In 2023, Agilent Technologies, Inc. partnered with Akoya Biosciences, Inc. to co-develop multiplex immunohistochemistry (IHC) diagnostic solutions. This collaboration aims to commercialize workflow solutions for multiplex assays in tissue analysis, offering an advanced multiplex IHC solution for biomarker clinical research, leveraging the capabilities of digital pathology.
In 2022, F. Hoffmann-La Roche Ltd, headquartered in Switzerland, obtained FDA approval for the label expansion of the VENTANA MMR RxDx Panel. This approval signifies an enhanced capability for the panel in identifying mismatch repair deficiencies, contributing to advanced diagnostics and personalized treatment strategies in the US.
In 2022, F. Hoffmann-La Roche Ltd obtained FDA approval for its PATHWAY anti-HER2/neu (485) Rabbit Monoclonal Primary Antibody. This antibody serves as a companion diagnostic test, aiding in the identification of metastatic breast cancer patients exhibiting low HER2 expression. The approval enhances precision in determining suitable treatment strategies for this specific patient population.
In 2021, Roche introduced the DISCOVERY Green HRP Chromogen Detection Kit, aiming to broaden immunohistochemistry multiplexing capabilities in cancer research. This kit enhances the detection of multiple biomarkers simultaneously, facilitating more comprehensive and detailed analysis in the field of cancer diagnostics and research.
These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the US Tissue Diagnostics Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.
US Tissue Diagnostics Market - Significant Threats
The US Tissue Diagnostics Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:
Stringent Regulatory Environment: The US Tissue Diagnostics Market faces threats from evolving and stringent regulatory requirements. Compliance challenges can increase operational costs and pose obstacles to obtaining timely product approvals, affecting market entry and growth.
Data Security and Privacy Concerns: The increasing reliance on digital pathology and electronic health records introduces potential threats related to data security and patient privacy. Cybersecurity risks and data breaches may undermine confidence in tissue diagnostics technologies, impacting market acceptance.
High Implementation Costs: The initial costs associated with implementing advanced tissue diagnostic technologies can act as a significant barrier. This financial challenge may limit adoption, particularly for smaller healthcare facilities, hindering market growth.
Competition from Alternative Diagnostic Methods: Emerging alternatives such as liquid biopsies and molecular diagnostics pose a competitive threat. These alternatives offer less invasive approaches, potentially diverting demand away from traditional tissue-based diagnostic methods and affecting market share.
Supply Chain Disruptions: The US tissue diagnostics market's reliance on a complex global supply chain for reagents, equipment, and consumables makes it susceptible to disruptions. Events like geopolitical tensions, natural disasters, or health crises can lead to shortages and impact the availability of essential components.
Category-Wise Insights
By Technology:
In Situ Hybridization (ISH): In Situ, Hybridization in the US Tissue Diagnostics Market involves localizing nucleic acid sequences in tissues. Trends include an increased application in molecular diagnostics, aiding in the precise identification of genetic abnormalities and biomarkers, and contributing to personalized medicine.
Immunohistochemistry (IHC): Immunohistochemistry employs antibodies to detect proteins in tissues. In the US Tissue Diagnostics Market, trends involve advanced antibody development, expanding diagnostic applications, and a growing emphasis on multiplex staining for comprehensive analysis.
Digital Pathology and Workflow: Digital Pathology integrates advanced imaging for efficient pathology workflows. In the US Tissue Diagnostics Market, trends include widespread adoption of remote diagnostics, AI integration for image analysis, and enhanced collaboration among pathologists for improved patient care.
Primary and Special Staining: Primary and Special Staining in the US Tissue Diagnostics Market involves coloring tissues for microscopic examination. Trends include automation for standardized staining, rapid turnaround times, and customization to meet diverse diagnostic needs.
Anatomic Pathology: Anatomic Pathology in the US Tissue Diagnostics Market encompasses the study of tissues for disease diagnosis. Trends involve an increased focus on personalized medicine, molecular diagnostics integration, and advancements in techniques for more precise disease characterization.
By Application
Prostate Cancer: Tissue diagnostics for prostate cancer involve the examination of prostate tissues. Trends include an increasing focus on personalized treatment approaches, the adoption of biomarker-driven diagnostics, and advancements in imaging technologies for accurate staging.
Breast Cancer: Breast cancer tissue diagnostics assess breast tissue abnormalities. Trends include a surge in HER2 testing, expanding applications of liquid biopsies, and a growing emphasis on molecular profiling for tailored therapeutic strategies.
Lung Cancer: Tissue diagnostics for lung cancer analyze lung tissues for abnormalities. Trends involve a rising adoption of companion diagnostics, utilization of minimally invasive procedures, and the integration of immunohistochemistry for comprehensive tumor characterization.
Gastric Cancer: Tissue diagnostics for gastric cancer examine stomach tissues. Trends encompass an increasing role of molecular testing for targeted therapies, advancements in endoscopic biopsy techniques, and a focus on identifying specific biomarkers for prognosis and treatment planning.
Other Cancer: Tissue diagnostics for various cancers beyond the mentioned types. Trends include a growing adoption of next-generation sequencing for comprehensive genomic profiling and an increased focus on multiplex immunohistochemistry for a detailed understanding of tumor biology and heterogeneity.
By End User
Research Laboratories: Research laboratories in the US Tissue Diagnostics Market conduct detailed studies for diagnostic advancements. Trends include a shift towards molecular diagnostics and increased utilization of digital pathology to enhance research precision and efficiency.
Hospitals: Hospitals in the US Tissue Diagnostics Market provide vital diagnostic services. Trends involve digital pathology integration, personalized medicine adoption, and an emphasis on point-of-care diagnostics for enhanced patient care.
Contract Research Organizations (CROs): Contract Research Organizations (CROs) play a crucial role in clinical research. Trends include rising demand for multiplex assays, advanced imaging technologies, and customized diagnostic solutions for research studies.
Pharmaceutical Organizations: Pharmaceutical organizations leverage tissue diagnostics for drug development. Trends include a focus on companion diagnostics, biomarker identification for targeted therapies, and collaborations with diagnostic companies to streamline the drug development process.
Report Scope
Feature of the Report
Details
Market Size in 2023
USD 2,017.2 Million
Projected Market Size in 2032
USD 3,655.5 Million
Market Size in 2022
USD 1,903.5 Million
CAGR Growth Rate
6.8% CAGR
Base Year
2023
Forecast Period
2024-2033
Key Segment
By Technology, Application, End Users and Region
Report Coverage
Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Country Scope
US
Buying Options
Request tailored purchasing options to fulfil your requirements for research.
Competitive Landscape – US Tissue Diagnostics Market
The US Tissue Diagnostics Market is highly competitive, with a large number of manufacturers and retailers operating. Some of the key players in the market include:
Danaher Corporation
Agilent Technologies Inc.
Bio-Rad Laboratorie, Inc.
Siemens Healthineers
Leica Biosystems Nussloch GmbH
Becto, Dickinson and Company (BD)
Sysmex Corporation
Illumina Inc.
PerkinElmer Inc.
Merck KGaA
Cell Signaling Technology Inc.
Hologic Inc.
Roche Diagnostics Corporation
Thermo Fisher Scientific Inc.
Abbott Laboratories
Others
These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.
Emerging entrants like Guardant Health and Foundation Medicine are pioneers in adopting innovations such as liquid biopsies and advanced sequencing technologies, entering the US Tissue Diagnostics Market with a focus on precision medicine and molecular diagnostics, contributing to market dynamism and evolution.
Established leaders, including Roche Diagnostics, Thermo Fisher Scientific, and Danaher Corporation, dominate the US Tissue Diagnostics Market. Their market dominance is rooted in extensive R&D, diverse product portfolios, strategic acquisitions, and strong collaborations, ensuring a comprehensive suite of tissue diagnostic solutions and reinforcing their market leadership.
US Tissue Diagnostics Market 2023–2032 (By Million)
Which are the driving factors of the US Tissue Diagnostics Market?
The key factors driving the Market are Technological Advancements, Rising Incidence of Chronic Diseases, Aging Population, Government Initiatives and Healthcare Investments, Integration of Artificial Intelligence (AI) And Collaborations and Research Partnerships.
Which application had the largest market share in the market?
The "Prostate Cancer" had the largest share in the global market for US Tissue Diagnostics.
Which type led the US Tissue Diagnostics marke
The "In Situ Hybridization" category dominated the market in 2022.
Who are the key players in the US Tissue Diagnostics market?
The key players in the market are Danaher Corporation, Agilent Technologies Inc., Bio-Rad Laboratorie, Inc., Siemens Healthineers, Leica Biosystems Nussloch GmbH , Becto, Dickinson and Company (BD), Sysmex Corporation, Illumina Inc., PerkinElmer Inc., Merck KGaA, Cell Signaling Technology Inc., Hologic Inc., Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Others.
What is the growth rate of the US Tissue Diagnostics market?
The global market is projected to grow at a CAGR of 6.8% during the forecast period, 2023-2032.
How much is the US Tissue Diagnostics market?
The US Tissue Diagnostics Market size was valued at USD 2,017.2 Million in 2023.
Ayush Kadam is a Senior Market Research Analyst at Custom Market Insights, with over seven years of experience in syndicated and custom market research. He specializes in market sizing, competitive intelligence, industry trends, forecasting, and strategic insights, helping clients turn complex data into actionable business decisions.
